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Summary The characteristics of a method for measuring cyclic AMP binding proteins in cytosols of human
breast cancer are described. Using the assay, binding proteins were demonstrable in all of 100 tumour
cytosols. Levels of binding in individual tumours varied from 0.8 to 15pmolmg-1 cytosol protein (mean
value 5pmolmg-' cytosol protein) and the dissociation constant ranged from 0.5 to 5.2 x 10-8M (mean
1.73 x 10-8M). Whilst replicate measurements within a single portion of tumour were reproducible (intra-
assay coefficient of variation was between 4.5 and 7.8% and that for inter-assay variation was between 2.1
and 4.0%) there were often considerable differences in levels of binding proteins between different portions of
the same tumour. Similar intra-tumour variations have been reported for other binding proteins and steroid
receptors. The inter-relationships with such parameters may elucidate whether the differences are associated
with variations in cellularity, cell type, or other specific factors.
In experimental animals, cyclic AMP binding
proteins are implicated in the growth of mammary
tumours (Cho-Chung, et al., 1978b; Bodwin, et al.,
1980; Bodwin et al., 1981). The corresponding
evidence in human breast cancers has yet to be
fully documented. In the present paper we describe
a method for measuring total cyclic AMP binding
proteins in human breast tumour cytosols and some
characteristics of the assay.
Materials and methods
Reagents
(5'8'-3H) Adenosine 3',5'-cyclic phosphate,
ammonium salt (45 Cimmol) was obtained from
Radiochemical Centre, Amersham, and radioinert
adenosine 3'5'-cyclic phosphate, sodium salt from
Sigma (Poole, UK). The following buffers were
employed using analytical reagents - Buffer A
20mM Tris, 0.25 M sucrose, 2mM magnesium
chloride, I mM calcium chloride, 1OmM potassium
chloride, 16.26mM HCI pH 7.5; Buffer B 55mM
potassium phosphate to which 11 mM theophylline
was added immediately before use; Buffer C as
Buffer B but with the addition of 10mM
magnesium chloride.
Tissues
Breast cancers were obtained at mastectomy or
biopsy from patients with histologically proven
disease. All material was transported on ice to a
cold room and processed immediately unless stated
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otherwise. The tumours represented 100 consecutive
cases in which sufficient material was available for
assay after tissue had been taken for routine
histopathological examination and for oestrogen
receptor analysis. Specimens were obtained from
patients with T stage 1 to 4, although the number
of TI tumours was small.
Cytosol preparation
All procedures were performed at 0-40C. Tumour
was dissected from surrounding fat and connective
tissue, finely cut with scissors and homogenized in
Buffer A (w/v :10) using a Silverson homogenizer
at maximum speed for 20 sec then 15 sec, with 1
min interval for cooling. The homogenate was
centrifuged at 105,000g for 1 h in a MSE
Superspeed 50 centrifuge and the resulting super-
natant was used as cytosol.
Binding measurements
Cytosol (50,ul) was incubated with 100pl 5',8'-[3H]
cyclic AMP (25nM to give a final concentration in
the incubation system of 10nM) and Buffer B
(100pI) containing radioinert cyclic AMP (final
concentration 0,10,20,40,80, and 10,000 nM). Each
system was set up in duplicate and incubated at
room temperature for 3 h. To separate protein-
bound cyclic AMP from free nucleotide, 2 ml
Buffer B was added to each tube. The contents
were then mixed and filtered through a Millipore
filter (HAWP 0.45 um) at 5mm Hg negative
pressure followed by 20ml Buffer C at 10mm Hg
negative pressure. The filters were transferred to
scintillation vials and dried under a stream of air.
Micellar fluor NE 260, Nuclear Enterprises (5ml)
was added to each vial. The vials were then
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incubated at 37°C for 2h and radioactivity was
measured in a Tricarb liquid scintillation counter
(Packard).
Cytosolprotein
The protein content of each cytosol was determined
by the method of Bradford (1976) using bovine
serum albumin as standard.
Results
Assay conditions
Tumour cytosols were incubated with [3H] cyclic
AMP in the absence and presence of 10,000 nM
radioinert cyclic AMP for varying times, either at
0°C or 20°C. A typical result is presented in Figure
1. Maximum binding at 20°C was achieved by 2h.
Binding at 0°C was lower than at 200C at each time
point studied but was still increasing at 5 h
incubation. Overnight incubation at either 0°C or
20°C produced similar binding (data not shown).
For routine assays it was decided to incubate at
20°C for 3 h. The amount of binding under these
conditions was linear with respect to increasing
cytosol protein concentrations up to at least
3.0mgml-1 (Figure 2). The effect of radioinert
cyclic AMP on the binding of [3H] cyclic AMP is
shown in Figure 3(a). Low concentrations of
radioinert cyclic AMP were able to compete with
[3H] cyclic AMP for binding, and there remained
only a low level of non-specific binding in the
presence of a thousand-fold excess of competitor.
The data plotted according to Scatchard (1949),
showed that the dissociation constant of binding
was 2.7 x 10-8M and that the maximum
concentration of binding sites within the assay
system was about 2.0 nM (Figure 3b). Similar
results were also obtained by performing the assay
with increasing concentrations of radio-labelled
ligand and assessing the non-specific binding by
including a 100-fold excess of cold competitor at
each of these concentrations (data not shown).
Values in breast cancer cytosols
Cytosols from 100 primary breast cancers have
been assayed for cyclic AMP binding proteins. The
results are presented in Table I, and the concen-
tration of binding sites in individual tumours are
plotted in Figure 4. All tumours showed cyclic
AMP binding but levels varied greatly between
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Figure 1 The effect of time of incubation on the
binding of [3H] cyclic AMP to a cytosol of breast
carcinoma either at 20°C (0) or 0°C (0). Each point
represents the amount of [3H] cyclic AMP bound in
the absence of radioinert cyclic AMP corrected for
that in the presence of 10,000 nm cold competitor.
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Figure 2 The effect of cytosol concentration on the
binding of [3H] cyclic AMP to cytosols of 2 different
breast carcinomas. Cytosols were prepared as
described in Materials and methods and serially diluted
to give the protein concentrations indicated. The
diluted cytosols were incubated for 3h at 20°C with
increasing concentrations of radioinert cyclic AMP.
The data were analysed by Scatchard plot and each
point represents the maximum number of binding sites
for each system.
Table I Levels and dissociation constants of cyclic AMP
binding proteins in cytosols of 100 primary breast cancers
Level Dissociation Constant
pmolmg-1 cytosolprotein (M x 10-8)
Mean+sd 4.99 + 3.07 1.72 ± 0.96
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Figure 3 The effect of radioinert cyclic AMP on the binding of [3H] cyclic AMP to a cytosol of human
breast cancer. Assay conditions were as described in Materials and methods, data plotted as (a) radioactivity



























Figure 4 Levels of cyclic AMP binding proteins in
cytosols of 100 primary breast cancers. Horizontal line
represents mean value.
Reproducibility ofmeasurements and effect of
storage
In order to determine the intra-assay precision of
cyclic AMP binding measurements in tumours,
large breast cancers were finely minced. Five
portions, each of
- 500 mg, were accurately
weighed and cytosols were prepared separately and
assayed. Two tumours were processed in this way;
one possesed a mean value for cyclic AMP binding
proteins from the 5 replicate estimations of
1.38pmolmg-1 cytosol protein with an intra-assay
coefficient of variation of 7.9%, the other cancer
had a mean value of 7.48pmolmg-1 cytosol
protein with an intra-assay coefficient of variation
of 4.5%.
To ascertain the interassay variation, 3 tumours
were divided into 5 portions, as described for the
study of intra-assay varitaion. One portion of each
tumour was assayed for cyclic AMP binding
proteins immediately (day 0) and the remaining
portions were stored in separate vials in liquid
nitrogen for 1,3,7 and 14 days until assayed. The
results are shown in Figure 5. There appeared to be
no observable decline in level of binding proteins
with storage, and considering measurements within
the same tumour as replicate estimates, the interassay
coefficients of variation were 2.1%, 2.5% and 4.0%
(that these values are lower than those for the intra-
assay variation is probably a reflection of the larger
number ofsimultaneous estimations performed in the
study of intra-assay variation).
An estimate of the variation in cyclic AMP
binding protein levels within individual cancers was
obtained by dissecting out portions of tumours
from central, intermediate and peripheral zones
across each of 12 large breast cancers. These were
assayed by the routine method and the results are
presented in Figure 6 as ratios of the values relative
to that in the peripheral zone. Whilst the mean of
the 12 values found in each tumour zone were
similar (and hence the mean value for the zone
ratio was unity), there were often large variations in
cyclic AMP binding protein levels between different
0
.
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Figure 5 The effect of storage in liquid nitrogen on
reproducibility of cyclic AMP binding protein levels in













Figure 6 Variation in cyclic AMP binding protein
levels across 12 breast cancers. For experimental
details, see text. Results have been expressed as a ratio
of the value obtained from the intermediate area (I) or
the central area (C) to that in the peripheral area (P).
areas in an individual tumour. This variation was
invariably greater when comparing central and
peripheral zones.
Discussion
Measurements of cyclic AMP binding proteins in
experimental animal cancers have yielded useful
information regarding the state of automony of the
tumours (Cho-Chung et al., 1980a; Bodwin et al.,
1980). Similar data in human breast cancers has not
yet been fully assessed. In the present paper we
describe the characteristics of an assay which might
be used routinely to measure total binding sites for
cyclic AMP in cytosols of human breast cancers.
This method involves incubating tumour cytosol
with radioactively labelled cyclic AMP in the
absence and presence of increasing concentrations
of radioinert competitor. At 20°C, maximum
binding was achieved by 2h and was linear between
cytosol protein concentrations of 0.4 and
3mgml-1. Under these conditions the non-specific
binding assessed by adding 1000-fold excess of
radioinert cyclic AMP was negligible (<0.1% of
the added radioactivity). The binding capacity was
not affected by storage up to 14 days in liquid
nitrogen. The intra-assay coefficent of variation, as
determined on aliquots from minced large tumours,
was between 4.5 and 7.9%, and the inter-assay
value was between 2.1 and 4.0%. These results are
similar to those obtained by others using a different
method (Kvinnsland et al., 1983).
Using the present method, cytosols of 100 human
breast cancers have been assayed for cyclic AMP
binding. All possessed binding activity, levels
varying from 0.8 to 15.0pmolmg-1 cytosol protein
(mean value 5pmolmg- cytosol protein). These
values fall within the range for human breast
cancer cytosols reported by others using different
methods (Eppenberger et al., 1980; Kvinnsland et
al., 1983), and are also similar to those found in rat
mammary tumours (Cho-Chung 1978a; Cho-
Chung et al., 1978b). The mean dissociation
constant of 1.73 x 10-8M is also in keeping with
data from experimental animal tumours (Cho-
Chung et al., 1978b).
It remains to determine which factors influence
the levels of cyclic AMP binding proteins in
cytosols of individual human breast cancers and, in
particular, whether these levels are related to
prognosis or endocrine responsiveness, as has been
suggested by others (Kvinnsland et al., 1983) and as
is the case in rat mammary tumours (Cho-Chung
1978a, b, 1980). Assessments in breast cancers will
have to take into account the variation in cyclic
AMP binding proteins between different areas of
the same tumour. Data from the present study
shows that there may be considerable differences in
the level of cyclic AMP binding between each of
three different areas (central, peripheral and inter-
mediate) of large tumours. No consistent pattern of
variation across the tumours was evident and the
mean value for cyclic AMP binding in this group of
cancers was similar, irrespective of the area of
tumour upon which the estimation was performed.
At present, it is not known whether theseCYCLIC AMP BINDING IN BREAST CANCER 535
differences within tumours are associated with
variations in cellularity, cell type or other factors.
Similar intra-tumour variations have been noted
with other binding proteins such as the oestrogen
receptor (Hawkins et al., 1977; Silversward et al.,
1980) and the inter-relationship with these different
types of binding protein may help to elucidate the
problem.
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